Mesoblast limited (ADR) (MESO) was Reiterated by Maxim Group to “Buy” while Lowering the Price Target of the company shares to $ 14 from a previous price target of $18 . Maxim Group advised their investors in a research report released on May 10, 2016.
Many Wall Street Analysts have commented on Mesoblast limited (ADR). Mesoblast limited (ADR) was Downgraded by JP Morgan to ” Neutral” on Mar 7, 2016. Chardan Capital Markets Initiated Mesoblast limited (ADR) on Feb 19, 2016 to “Neutral”, Price Target of the shares are set at $5.50.
Mesoblast Limited is engaged in the development of adult stem cell technology platform for commercialization. The Company develops a portfolio of regenerative therapeutic cell-based products. Its portfolio of therapeutic products is being developed using its technology platforms which include specialized cells known as mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs including cardiac diseases spine and musculoskeletal disorders oncology and hematology diseases and immune-mediated and inflammatory conditions. Its products have been prioritized into two tiers: tier 1 product candidates which represents its lead programs where it focuses on time and resources such as MPC-06-ID MPC-150-IM JR-031 MPC-300-IV and MSC-100-IV and tier 2 product candidates which advances to tier 1 depending on newly-generated data market opportunity or partnering options such as MSC-100-IV MPC-25-IC MPC-25-Osteo and MPC-CBE.